Siemens’ oncology group wins award
The Siemens Oncology Care Systems Group won California Governor Gray Davis’ 1999 Quality Award for Overall Excellence for its work in oncology. This award recognizes overall excellence in all business areas, including management, marketplace,
The Siemens Oncology Care Systems Group won California Governor Gray Davis 1999 Quality Award for Overall Excellence for its work in oncology. This award recognizes overall excellence in all business areas, including management, marketplace, workplace, and community. The Oncology Care Systems Group, based in Concord, CA, was founded in 1974. It manufactures and develops radiation therapy products for the worldwide oncology market. The group has brought intensity-modulated radiation therapy (IMRT) to smaller clinics across the U.S. IMRT is usually found in large hospitals. This treatment delivers complex doses of radiation to tumors while minimizing the effect on surrounding tissue.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
